{"organizations": [], "uuid": "1b91b9863caf115f1b15686dd14c3dddd1496268", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/UKBusinessNews/", "section_title": "Reuters: Business News", "url": "https://uk.reuters.com/article/uk-hikma-pharma-outlook/drugmaker-hikma-says-generics-doing-well-amid-pricing-pressure-idUKKCN1IJ0J3", "country": "US", "domain_rank": 408, "title": "Drugmaker Hikma says generics doing well amid pricing pressure", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-18T09:42:00.000+03:00", "replies_count": 0, "uuid": "1b91b9863caf115f1b15686dd14c3dddd1496268"}, "author": "", "url": "https://uk.reuters.com/article/uk-hikma-pharma-outlook/drugmaker-hikma-says-generics-doing-well-amid-pricing-pressure-idUKKCN1IJ0J3", "ord_in_thread": 0, "title": "Drugmaker Hikma says generics doing well amid pricing pressure", "locations": [], "entities": {"persons": [{"name": "drugmaker hikma", "sentiment": "negative"}, {"name": "justin george varghese", "sentiment": "none"}], "locations": [{"name": "bengaluru", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "hikma pharmaceuticals plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18, 2018 / 6:42 AM / Updated 23 minutes ago Drugmaker Hikma says generics doing well amid pricing pressure Reuters Staff 1 Min Read\n(Reuters) - Hikma Pharmaceuticals Plc ( HIK.L ) said its generics business had a good start to the year helped by a favourable product mix, despite continued pricing pressure in the United States.\nThe drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million (407 million pounds) and $600 million, and core operating margin in the low-single digits.\nThe Jordan-based company reaffirmed its guidance for the full year. Reporting By Justin George Varghese in Bengaluru", "external_links": [], "published": "2018-05-18T09:42:00.000+03:00", "crawled": "2018-05-18T09:57:12.013+03:00", "highlightTitle": ""}